A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With An Open-Label Extension Evaluating Extended Release OROS Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With An Open-Label Extension Evaluating Extended Release OROS Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 18 Jul 2016 Result of post-hoc analysis of this and one other phase III trial published in the International Clinical Psychopharmacology (2016).
    • 14 Sep 2010 US FDA approved NDA for paliperidone for the acute and maintenance treatment of schizophrenia based data from this and other pivotal trials.
    • 12 Dec 2007 The open-label extension phase of this trial has been completed, according to the media release of Janssen L.P. The open-label trial included 235 patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top